Hodgkin lymphoma (HL): Diagnosis, Treatment and Side Effect Management (Nurse)

Credit Available: ASWB,CABRN, NP

Enroll in this Course

FREE
access until July 31, 2025 12:00 am

Activity Description

Waiting for what LLS has

Time to Complete Activity: 1.50 hours

This course is available from:

July 9, 2024 until August 30, 2025

Course Instructors

David Awad, Pharm D, BCOP Speaker

Clinical Pharmacist Specialist, Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Matthew Matasar, MD Speaker

Chief of Blood Disorders, Rutgers Cancer Institute of New Jersey,  New Brunswick, NJ

Tara McCabe, APN, AOCNP, MSN Speaker

Advanced Practice Nurse, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Target Audience

Oncology nurse practitioners, nurses, and social workers involved in the care of patients with Hodgkin lymphoma (HL).

Course Content Level for Social Workers — all levels

Format: Non-interactive recorded webinar

Educational Objectives
After completing this activity, the participant should be better able to:

    • Describe the various subtypes of Hodgkin lymphoma (HL)
    • Identify tests used to diagnose disease and monitor treatment of HL
    • Explain the overarching goals of treatment for the subtypes of HL
    • Explain approved and emerging treatment options for HL, including stem cell transplantation, and the role of clinical trials
    • Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments for HL
Accreditation, Support and Credit
Nursing Continuing Professional Development

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.

Social Worker Continuing Education

The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.5 clinical continuing education credits.

The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.5 clinical CE contact hours for this activity.

Nurse Practitioner Continuing Education

This education activity will be submitted to the American Association of Nurse Practitioners® for approval of up to XX contact hours of accredited education.

 

Support Statement

There is no commercial support associated with this CE activity.

Provider

This activity is provided by The Leukemia & Lymphoma Society.


Disclosure of Conflicts of Interest Policy

All persons who may impact the content of a CE activity, including faculty and planners, are required to fully disclose current and recent financial relationships with commercial interests. A conflict of interest may be considered to exist if such a person has financial relationships with the grantor or any non-eligible entities (commercial interests) that may have a direct impact on the content of the program. Financial relationship is defined as being a shareholder, consultant, grant recipient, research participant, employee, and/or recipient of other financial or material support. Recent is defined as within the past 24 months. The participants in this CE activity must be made aware of any such financial relationship(s). This disclosure policy is intended to protect all parties involved from any potential conflict of interest that may arise.

Faculty Disclosures

David Awad, Pharm D, BCOP, has no financial relationships with ineligible companies.

Matthew Matasar, MD, has financial relationships with the following companies:
Advisory Board/Consultant: Bayer, Genetech, Juno Therapeutics, Merck, Roche, Seattle Genetics, Takeda, Teva
Research/Grant: ADC Therapeutics, Bayer, Genetech, GM Biosciences, Immunovaccine Technologies, Pharmacyclics
Honorarium: ADC Therapeutics, AstraZeneca

Stock: Merck
Other: AstraZeneca, Epizyme, Kite, Seagen, Roche, Seattle Genetics, Pharmacyclics, Seattle Genetics, Takeda

Tara McCabe, APN, AOCNP, MSN, has no financial relationships with ineligible companies.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from The Leukemia & Lymphoma Society do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Lauren Berger, MPH, has a financial interest/relationship or affiliation in the form of:
Stock Ownership with Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. 

If you have questions regarding your certificate, please contact Nicole Dane via email at ndane@kimeglobal.com.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.

  • Resources for You
  • Resources for Patients
  • FREE CME and CE courses for healthcare professionals: www.LLS.org/CE
  • Treating Blood Cancers: Podcast series for healthcare professionals: www.LLS.org/HCPpodcast. Experts discuss the latest developments in blood cancers, new and emerging treatment options, side-effect management, survivorship issues, and more.
  • Free Fact Sheets for HCPs: www.LLS.org/HCPbooklets
  • LLS Online Community: HCP, Patient/Survivor & Caregiver account types: www.LLS.org/community
    • Safe and secure site dedicated to research and has been created to support those living with blood cancer, their closest family members and healthcare professionals.
  • Clinical Trial Nurse Navigators:  Patients, caregivers, & HCPs, can work one-on-one with an LLS Clinical Trial Nurse Navigator who will help find clinical trials and personally assist throughout the clinical trial process, providing an additional resource to the HCP team –  www.LLS.org/CTSC
  • Information Resource Center: Information Specialists are highly trained social workers and nurses who assist through treatment, financial, and social challenges. They offer up-to-date disease and treatment information. Language services are available. – www.LLS.org/IRC
  • Hodgkin lymphoma: www.LLS.org/hodgkin-lymphoma
  • Telephone and web education programswww.LLS.org/Programs 
  • Education Videos: www.LLS.org/Educationvideos
  • Podcasts: www.LLS.org/podcast
  • Free booklets and fact sheets on disease, treatment and survivorshipwww.LLS.org/Booklets
  • Support resources: www.LLS.org/Support
    • Financial assistance
      • Co-Pay
      • Travel Assistance
      • Referral to medication access programs
      • Patient Aid
      • Urgent Need
      • Veteran Dental Financial Assistance (See website for location and application details)
    • LLS regions
    • LLS Community (social media platform)
    • Weekly online chats (facilitated by oncology social workers)
    • Patti Robinson Kaufman First Connection Program (peer-to-peer)
    • Nutrition Education Services Center (1:1 nutrition consultation with registered dietitians)
    • Clinical Trial Support Center Nurse Navigators: Patients & caregivers work one-on-one with an LLS Clinical Trial Nurse Navigator who will help find clinical trials and personally assist throughout the clinical trial process, providing an additional resource to the HCP team – www.LLS.org/CTSC
    • Information Resource Center: Information Specialists are highly trained social workers and nurses who assist through treatment, financial, and social challenges. They offer up-to-date disease and treatment information. Language services are available. – www.LLS.org/IRC

If you have any questions, please contact us at ProfEducation@LLS.org or call our Information Resource staff at (800)-955-4572.

Scroll to Top